Bedi, G., Phan, K. L., Angstadt, M., & de Wit, H. (2009). Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl), 207(1), 73-83. https://doi.org/10.1007/s00213-009-1635-z
Cami, J., Farré, M., Mas, M., Roset, P. N., Poudevida, S., Mas, A., . . . de la Torre, R. (2000). Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol, 20(4), 455-466. https://doi.org/10.1097/00004714-200008000-00010
Downing, J. (1986). The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs, 18(4), 335-340. https://doi.org/10.1080/02791072.1986.10472366
Grob, C. (1998). MDMA research: Preliminary investigations with human subjects. Int J Drug Policy, 9(2), 119-124.
Harris, D. S., Baggott, M., Mendelson, J. H., Mendelson, J. E., & Jones, R. T. (2002). Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl), 162(4), 396-405. https://doi.org/10.1007/s00213-002-1131-1
Kirkpatrick, M. G., Gunderson, E. W., Perez, A. Y., Haney, M., Foltin, R. W., & Hart, C. L. (2012). A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4- methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl), 219(1), 109- 122. https://doi.org/10.1007/s00213-011-2383-4
Kolbrich, E. A., Goodwin, R. S., Gorelick, D. A., Hayes, R. J., Stein, E. A., & Huestis, M. A. (2008). Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol, 28(4), 432-440. https://doi.org/10.1097/JCP.0b013e31817ef470
Lester, S. J., Baggott, M., Welm, S., Schiller, N. B., Jones, R. T., Foster, E., & Mendelson, J. (2000). Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo- controlled trial. Ann Intern Med, 133(12), 969-973. https://doi.org/10.7326/0003-4819-133-12- 200012190-00012
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001). Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl), 154(2), 161-168. https://doi.org/10.1007/s002130000648
Mas, M., Farré, M., de la Torre, R., Roset, P. N., Ortuño, J., Segura, J., & Camí, J. (1999). Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther, 290(1), 136-145.
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., . . . Doblin, R. (2019). MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl), 236(9), 2735-2745. https://doi.org/10.1007/s00213-019-05249-5
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol, 25(4), 439-452. https://doi.org/10.1177/0269881110378371
Oehen, P., Traber, R., Widmer, V., & Schnyder, U. (2013). A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol, 27(1), 40-52. https://doi.org/10.1177/0269881112464827
Rush, B., Marcus, O., Shore, R., Cunningham, L., Thomson, N., and Rideout, K. (2022). Psychedelic Medicine: A Rapid Review of Therapeutic Applications and Implications for Future Research. Homewood Research Institute. https://hriresearch.com/research/exploratory- research/research-reports/
Schwartz, R. H., & Miller, N. S. (1997). MDMA (ecstasy) and the rave: a review. Pediatrics, 100(4), 705-708. https://doi.org/10.1542/peds.100.4.705
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacology, 19(4), 241-251. https://doi.org/10.1016/s0893-133x(98)00013-x